Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease

• Published in: Frontiers in immunology 2021-06, Vol.12, p.636731-636731
• Main Authors: De Groot, Anne S., Desai, Ankit K., Lelias, Sandra, Miah, S. M. Shahjahan, Terry, Frances E., Khan, Sundos, Li, Cindy, Yi, John S., Ardito, Matt, Martin, William D., Kishnani, Priya S.
• Format: Article
• Language: English
• Subjects: acid alpha-glucosidase (GAA); anti-drug antibodies (ADA); cross-reactive immunological material (CRIM); enzyme replacement therapy (ERT); immune tolerance induction (ITI); Immunology; Pompe Disease (glycogen storage disease type II)
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2021.636731

Infantile-onset Pompe disease (IOPD) is a glycogen storage disease caused by a deficiency of acid alpha-glucosidase (GAA). Treatment with recombinant human GAA (rhGAA, alglucosidase alfa) enzyme replacement therapy (ERT) significantly improves clinical outcomes; however, many IOPD children treated with rhGAA develop anti-drug antibodies (ADA) that render the therapy ineffective. Antibodies to rhGAA are driven by T cell responses to sequences in rhGAA that differ from the individuals’ native GAA (nGAA). The goal of this study was to develop a tool for p ersonalized im munogenicity risk a ssessment (PIMA) that quantifies T cell epitopes that differ between nGAA and rhGAA using information about an individual’s native GAA gene and their HLA DR haplotype, and to use this information to predict the risk of developing ADA. Four versions of PIMA have been developed. They use EpiMatrix, a computational tool for T cell epitope identification, combined with an HLA-restricted epitope-specific scoring feature (iTEM), to assess ADA risk. One version of PIMA also integrates JanusMatrix, a Treg epitope prediction tool to identify putative immunomodulatory (regulatory) T cell epitopes in self-proteins. Using the JanusMatrix-adjusted version of PIMA in a logistic regression model with data from 48 cross-reactive immunological material (CRIM)-positive IOPD subjects, those with scores greater than 10 were 4-fold more likely to develop ADA (p